Editorial Article
Simoa Technology aims to transform future Alzheimer's disease detection and treatment
Learn how biomarkers can be used to transform drug approval and patient management in neurodegenerative medicine
News & Articles
25
Selected Filters:
Product News
Quanterix granted Breakthrough Device designation from U.S. FDA for NfL test for multiple sclerosis
Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease
Product News
Quanterix granted Breakthrough Device designation from U.S. FDA for blood-based pTau-181 assay for Alzheimer’s Disease
The FDA’s Breakthrough Device designation is granted to products that have the potential to offer a more effective diagnosis of life-threatening diseases
Industry News
Quanterix’ Simoa technology powers largest and most diverse global investigation of plasma neurofilament light’s role in dementia diagnosis
The ultra-sensitive biomarker platform evaluates plasma neurofilament light’s utility across 13 neurodegenerative disorders, Down syndrome and depression
Product News
Quanterix' ultra-sensitive technology powers COVID-19 antibody test
Test deployed on Quanterix' Simoa platform promises 1,000-fold sensitivity improvement
Product News
Quanterix Launches High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection
New benchtop design and expanded assay portfolio offers researchers greater access to ultra-sensitive Simoa technology for biomarker detection
Industry News
Single Molecule MicroRNA Technology Proves Useful for Liver Toxicity Detection
Breakthrough research published in PLOS ONE demonstrates quantitative, PCR-free detection of microRNA
